Feng Xiao

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

Robin Kate Kelley, Ghassan K. Abou‐Alfa, Johanna C. Bendell et al. · Journal of Clinical Oncology · 2017 · 168 citations

Medicine, Oncology, Pharmacology +17

The epidemiological characteristics of 2019 novel coronavirus diseases (COVID-19) in Jingmen, Hubei, China

Qijun Gao, Yingfu Hu, Zhiguo Dai et al. · Medicine · 2020 · 73 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +15

Relationship Between Serum Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid and Organ Damage in Coronavirus 2019 Patients: A Cohort Study

Dan Xu, Fuling Zhou, Wenbo Sun et al. · Clinical Infectious Diseases · 2020 · 62 citations · Full text

Veterinary Medicine, Infectious Diseases, Internal Medicine +17

A Relationship between p27 ^kip1 and Skp2 after Adult Brain Injury: Implications for Glial Proliferation

Yonghua Liu, Youhua Wang, Chun Cheng et al. · Journal of Neurotrauma · 2009 · 50 citations

Life Sciences, Molecular Biology, Neuroscience +17

Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).

Jonathan W. Goldman, Afshin Dowlati, Scott Antonia et al. · Journal of Clinical Oncology · 2018 · 50 citations

Pharmacy, Oncology, Pharmacotherapy +17